BMCC-2022-P04

Synthetic Peptide of Tumor Associated Antigen L6-based Cancer Immunotherapy

BMCC

Synthetic Peptide of Tumor Associated Antigen L6-based Cancer Immunotherapy

未定中標題
BMCC Targeted indication

Lung, breast and colorectal cancer

BMCC Status

Preclinical study

BMCC Key features
  • High safety profile
  • Easy to manufacture
  • Less barrier to enter clinical trials
BMCC Market

Synthetic peptide is an attractive approach for cancer immunotherapy because of its safety and flexibility. Although there are many peptide-based cancer immunotherapy have been performed in clinical trials, synthetic peptide contains both B and T cell epitopes is very few. There are no synthetic peptide products have been used to target TAL6-associated cancers (lung cancer, Breast cancer, Colorectal cancer...etc). Our invention could be an innovative approach to treat cancers.

MODE OF ACTION

EXPERIMENTAL RESULTS

in vitro efficacy

Synthetic peptide immunization induced strong ADCC and CTL responses

 

 

in vivo efficacy

Peptide immunization can inhibit tumor growth and cancer cell migration

Safety pharmacology and general toxicology

Non-toxic in Single Dose Acute Toxicity Testing (At doses up to 10 times of the effective dose in animal).

INTELLECTUAL PROPERTY

Issued patent: 1 US and 1 ROC patents (T cell epitope)
Pending patent: US, ROC and PCT patent (B cell epitope)

SELECTED PUBLICATIONS

1. Lin et al. Cancer Letters.377(2):126-33.2016
2. Sher et al. Oncotarget, 2016 7(1):671-683
3. Tu et al. J. Immunotherapy. 35:235-244, 2012

BUSINESS OPPORTUNITY

License and/or Collaboration and Sponsored Research

CONTACT

service@biip-dcc.org

*欲下載完整檔案請 登入/ 會員註冊